These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2669100)

  • 1. Vibrio cholerae vaccines.
    Kaper JB
    Rev Infect Dis; 1989; 11 Suppl 3():S568-73. PubMed ID: 2669100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current status of cholera vaccine development and experience with cholera vaccine trials in volunteers.
    Levine MM; Kaper JB; Herrington D; Losonsky G; Tacket C; Tall B
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):401-15. PubMed ID: 3217822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An oral B subunit: whole cell vaccine against cholera.
    Holmgren J; Svennerholm AM; Jertborn M; Clemens J; Sack DA; Salenstedt R; Wigzell H
    Vaccine; 1992; 10(13):911-4. PubMed ID: 1471411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines.
    Kaper JB; Levine MM
    Res Microbiol; 1990; 141(7-8):901-6. PubMed ID: 2101480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholera toxin-B (ctxB) antigen expressing Salmonella Typhimurium polyvalent vaccine exerts protective immune response against Vibrio cholerae infection.
    Vishwakarma V; Sahoo SS; Das S; Ray S; Hardt WD; Suar M
    Vaccine; 2015 Apr; 33(15):1880-9. PubMed ID: 25701672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live attenuated oral cholera vaccines.
    Ryan ET; Calderwood SB; Qadri F
    Expert Rev Vaccines; 2006 Aug; 5(4):483-94. PubMed ID: 16989629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Texas Star-SR: attenuated "Vibrio cholerae" oral vaccine candidate.
    Levine MM; Black RE; Clements ML; Young CR; Lanata C; Sears S; Honda T; Finkelstein R
    Dev Biol Stand; 1983; 53():59-65. PubMed ID: 6873477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.
    Black RE; Levine MM; Clements ML; Young CR; Svennerholm AM; Holmgren J
    Infect Immun; 1987 May; 55(5):1116-20. PubMed ID: 3552989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The state-of-the-art of approved and under-development cholera vaccines.
    Pastor M; Pedraz JL; Esquisabel A
    Vaccine; 2013 Aug; 31(38):4069-78. PubMed ID: 23845813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
    Kenner JR; Coster TS; Taylor DN; Trofa AF; Barrera-Oro M; Hyman T; Adams JM; Beattie DT; Killeen KP; Spriggs DR
    J Infect Dis; 1995 Oct; 172(4):1126-9. PubMed ID: 7561195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
    Boustanshenas M; Bakhshi B; Ghorbani M
    J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
    Cryz SJ; Kaper J; Tacket C; Nataro J; Levine MM
    Dev Biol Stand; 1995; 84():237-44. PubMed ID: 7796960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral vaccines against cholera: lessons from Vietnam and elsewhere.
    Levine MM
    Lancet; 1997 Jan; 349(9047):220-1. PubMed ID: 9014902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for reacquisition of cholera enterotoxin genes by attenuated Vibrio cholerae vaccine strain CVD 103-HgR.
    Kaper JB; Michalski J; Ketley JM; Levine MM
    Infect Immun; 1994 Apr; 62(4):1480-3. PubMed ID: 8132356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
    Suharyono ; Simanjuntak C; Witham N; Punjabi N; Heppner DG; Losonsky G; Totosudirjo H; Rifai AR; Clemens J; Lim YL
    Lancet; 1992 Sep; 340(8821):689-94. PubMed ID: 1355798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.